Dr. Zhang Yu is the SVP&CSO of Vcanbio Cell&Gene Engineering Co.,Ltd (A listed company on Shanghai A stock). Prior to join Aeon, Dr. Zhang was president and CEO of Aeon Therapeutics, a joint-venture biotech company between Eureka Therapeutics Inc. and Vcanbio; assistant president in Vcanbio. Dr. Zhang received his B.S. in Bioengineering and M.S. in Biomedical Engineering from Beihang University, and a Ph.D. in Stem Cell and Regenerative Medicine from Heinrich-Heine-Universität Düsseldorf. In the period of Germany, he worked in Rhine Forum, University of Applied Sciences Bonn-Rhein-Sieg, and was a visiting scholar in German Aerospace Center and University of Palermo. He is a member of German Society of Stem Cell, Chinese Society of Cell Biology, and reviewer of several cell therapy journals, e.g. Current Stem Cell Research&Therapy. Dr. Zhang was the winner of “131 talent plan” and “Tianjin Green Card Plan”